<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02024464</url>
  </required_header>
  <id_info>
    <org_study_id>CP-10-002</org_study_id>
    <nct_id>NCT02024464</nct_id>
  </id_info>
  <brief_title>Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivantis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares two implantable devices intended to lower the pressure inside
      the eye of glaucoma patients. One of the two devices will be implanted immediately following
      cataract surgery and the placement of a posterior chamber intra-ocular lens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single-masked, randomized clinical trial comparing
      Cataract Extraction (CE) + Hydrus Microstent to CE surgery + iStent implant for the reduction
      of intraocular pressure in patients with a positive diagnosis of primary open angle glaucoma,
      pseudoexfoliative glaucoma, or pigmentary dispersion glaucoma with an operable cataract.
      Eligible patients will be scheduled for cataract surgery. At the conclusion of successful
      cataract surgery and the placement of a posterior-chamber IOL, qualified subjects will be
      randomized to receive either the Hydrus Microstent or the iStent implant. Post-operative
      follow-up visits will be conducted at regular intervals.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure at Month 12</measure>
    <time_frame>24 months</time_frame>
    <description>The primary effectiveness endpoint for this study is IOP at 24 months following surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring supplemental medication.</measure>
    <time_frame>24 months</time_frame>
    <description>The proportion of patients requiring supplemental medication for pressure control.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of eyes with IOP greater than 5 and less than or equal to 19 mmHg.</measure>
    <time_frame>24 months</time_frame>
    <description>The proportion of eyes with IOP greater than 5 and less than or equal to 19 mmHg at 24 months after surgery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Loss of best-corrected visual acuity (BCVA)</measure>
    <time_frame>24 months</time_frame>
    <description>Safety outcomes include loss of lines of BCVA, results of slit lamp and fundus examination, and the incidence of complications and adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Pseudoexfoliative Glaucoma</condition>
  <condition>Pigmentary Dispersion Glaucoma</condition>
  <arm_group>
    <arm_group_label>Hydrus Microstent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the Hydrus Microstent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iStent Trabecular Micro Bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the iStent Trabecular Micro Bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrus Microstent</intervention_name>
    <description>Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.</description>
    <arm_group_label>Hydrus Microstent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent Trabecular Micro Bypass</intervention_name>
    <description>Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.</description>
    <arm_group_label>iStent Trabecular Micro Bypass</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of primary open angle glaucoma (POAG), Pseudoexfoliative (PXG) glaucoma,
             or Pigmentary dispersion glaucoma (PDG)

          -  An operable age-related cataract with BCVA of 20/40 or worse, eligible for
             phacoemulsification.

        Exclusion Criteria:

          -  Forms of primary or secondary glaucoma not listed above

          -  Prior glaucoma surgery in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iqbal K. Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mississauga, ON, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Paul Rhee at Ivantis</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>POAG</keyword>
  <keyword>Pseudoexfoliative glaucoma</keyword>
  <keyword>PXG</keyword>
  <keyword>Pigmentary dispersion glaucoma</keyword>
  <keyword>PDG</keyword>
  <keyword>Hydrus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

